DURECT (NASDAQ:DRRX) Now Covered by StockNews.com

StockNews.com began coverage on shares of DURECT (NASDAQ:DRRX) in a report published on Sunday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating on shares of DURECT in a research report on Thursday, November 14th.

DURECT Trading Down 1.9 %

DURECT stock opened at $0.95 on Friday. The stock has a 50-day moving average price of $1.07 and a 200 day moving average price of $1.29. DURECT has a 52 week low of $0.51 and a 52 week high of $1.88. The stock has a market cap of $29.49 million, a PE ratio of -1.56 and a beta of 1.01.

Institutional Investors Weigh In On DURECT

Several large investors have recently made changes to their positions in the business. International Assets Investment Management LLC grew its stake in shares of DURECT by 41.3% in the second quarter. International Assets Investment Management LLC now owns 21,550 shares of the specialty pharmaceutical company’s stock valued at $28,000 after buying an additional 6,300 shares in the last quarter. Richmond Brothers Inc. boosted its holdings in DURECT by 39.5% in the 2nd quarter. Richmond Brothers Inc. now owns 1,072,014 shares of the specialty pharmaceutical company’s stock worth $1,383,000 after acquiring an additional 303,670 shares during the period. Finally, Geode Capital Management LLC grew its position in DURECT by 4.8% in the third quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock valued at $429,000 after acquiring an additional 14,658 shares in the last quarter. Institutional investors and hedge funds own 28.03% of the company’s stock.

About DURECT

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.